Related Experiment Video
Updated: Jul 19, 2026

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43
Published on: September 11, 2020
Vancomycin-tolerant Streptococcus pneumoniae in Korea
Heungsup Sung1, Hee Bong Shin, Mi-Na Kim
1Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, 388-1 Pungnap-dong, Songpa-ku, Seoul 138-736, Korea.
Abstract:
A nationwide surveillance study was undertaken to monitor antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Korea, with a special focus on vancomycin tolerance. For the 6-month period from March to August 2002, clinical isolates of S. pneumoniae were collected from 11 university hospitals and 1 reference laboratory. One-hundred eighty-eight isolates were measured for lysis rates after exposure to vancomycin for 4 h. Two vancomycin-tolerant S. pneumoniae (VTSP) strains, S3 and H8, were isolated from sputum cultures of two patients, who had stayed in intensive-care units of different hospitals with long-term antibiotic therapy and were not treated for pneumococcal pneumonia. The penicillin, cefotaxime, and vancomycin MICs for S3 were 8 microg/ml, >16 microg/ml, and 0.5 microg/ml, and those for H8 were 2 microg/ml, 2 microg/ml, and 0.5 microg/ml, respectively. While S3 belonged to serotype 23F and was autolysin defective, H8 belonged to serotype 13F and had intact autolysin. These strains were not clonally related as determined by pulsed-field gel electrophoresis of chromosomal DNA. In agreement with previous reports, both isolates showed pairing of TIGR4 vex2 with R6 pep27 and had two identical amino acid substitutions, Q441K in vncS and N25D in vex2. These findings indicate that two VTSP strains have emerged independently in Korea, suggesting a prevalence rate of 1.1%. The emergence of VTSP would be a serious threat in Korea, where there are significant rates of penicillin resistance in S. pneumoniae. Monitoring of the prevalence of VTSP and further investigation of the clinical relevance of VTSP are warranted.
Insights
Two vancomycin-tolerant Streptococcus pneumoniae (VTSP) strains emerged independently in Korea, indicating a 1.1% prevalence. This finding is a serious threat due to existing penicillin resistance in S. pneumoniae.
Area of Science:
- Microbiology
- Infectious Diseases
- Antimicrobial Resistance
Background:
- Streptococcus pneumoniae is a leading cause of bacterial infections worldwide.
- Antimicrobial resistance, particularly to penicillin, is a growing concern in S. pneumoniae.
- Vancomycin tolerance in S. pneumoniae is an emerging issue requiring surveillance.
Purpose of the Study:
- To monitor antimicrobial resistance in clinical isolates of S. pneumoniae in Korea.
- To specifically investigate the prevalence and characteristics of vancomycin-tolerant S. pneumoniae (VTSP).
Main Methods:
- Nationwide surveillance of S. pneumoniae clinical isolates from March to August 2002.
- Collection of isolates from 11 university hospitals and 1 reference laboratory.
- Measurement of lysis rates after vancomycin exposure and characterization of VTSP strains (serotyping, autolysin activity, PFGE, genetic analysis).
Main Results:
- Two VTSP strains (S3 and H8) were isolated from intensive-care unit patients.
- These strains exhibited specific penicillin, cefotaxime, and vancomycin MICs and belonged to different serotypes (23F and 13F).
- Genetic analysis revealed conserved amino acid substitutions in vncS and vex2, suggesting independent emergence with a prevalence rate of 1.1%.
Conclusions:
- Two VTSP strains have emerged independently in Korea.
- The prevalence of VTSP poses a significant threat, especially given high rates of penicillin resistance in S. pneumoniae.
- Continued monitoring and clinical relevance investigation of VTSP are warranted.
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Mechanism of Antibiotic Resistance in MRSA
Atypical Pneumonia
Streptococcal Pharyngitis
Development of Antibiotic Resistance
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
